Request a copy

Full Text

• Donn RP and Ray DW: Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule. J. Endocrinol 185: 1-9, 2004.
• Calandra T and Bucala R: Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. Crit Rev Immunol 17: 77-88, 1997. (Pubitemid 27068808)
• Calandra T and Roger T: Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3: 791-800, 2003. (Pubitemid 37328657)
• Mitchell RA and Buccala R: Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol 10: 359-366, 2000.
• Mitchell RA: Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal 16: 13-19, 2004.
• Bach JP, Deuster O, Balzer-Geldsetzer M, Meyer B, Dodel R and Bacher M: The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer 115: 2031-2040, 2009.
• Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ and Beach DH: A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190: 1375-1382, 1999.
• Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Lüscher B and Bernhagen J: Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 26: 5046-5059, 2007.
• Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X, Zarate R, Diaz-Gonzalez JA, Ramirez N, Sola JJ, Jimenez P, Rodriguez J and Garcia-Foncillas J: MicroRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res 15: 2281-2290, 2009.
• Kayser K, Bovin NV, Korchagina EY, Zeilinger C, Zeng FY and Gabius HJ: Correlation of expression of binding sites for synthetic blood group A-, B- and H-trisaccharides and for sarcolectin with survival of patients with bronchial carcinoma. Eur J Cancer 30A: 653-657, 1994.
• Bini L, Magi B, Marzocchi B, Arcuri F, Tripodi S, Cintorino M, Sanchez JC, Frutiger S, Hughes G, Pallini V, Hochstrasser DF and Tosi P: Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 18: 2832-41, 1997. (Pubitemid 28059956)
• Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M and Nishihira J: High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 264: 751-758, 1999.
• Kamimura A, Kamachi M, Nishihira J, Ogura S, Isobe H, Dosaka-Akita H, Ogata A, Shindoh M, Ohbuchi T and Kawakami Y: Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer 89: 334-341, 2000. (Pubitemid 30489881)
• Kayser K, Zink S, André S, Schüring MP, Hecker E, Klar E, Bovin NV, Kaltner H and Gabius HJ: Primary colorectal carcinomas and their intrapulmonary metastases: clinical, glyco-, immuno- and lectin histochemical, nuclear and syntactic structure analysis with emphasis on correlation with period of occurrence of metastases and survival. APMIS 110: 435-446, 2002.
• Kayser K, Dünnwald D, Kazmierczak B, Bullerdiek J, Kaltner H, Zick Y, André S and Gabius HJ: Chromosomal aberrations, profiles of expression of growth-related markers including galectins and environmental hazards in relation to the incidence of chondroid pulmonary hamartomas. Pathol Res Pract 199: 589-598, 2003.
• Legendre H, Decaestecker C, Nagy N, Hendlisz A, Schüring MP, Salmon I, Gabius HJ, Pector JC and Kiss R: Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Modern Pathol 16: 491-504, 2003.
• White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, Yee J, Orringer MB and Arenberg DA: Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 9: 853-860, 2003.
• Lee H, Rhee H, Rang HJ, Kim HS, Min BS, Kim NK and Kim H: Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas. Am J Clin Pathol 129: 772-779, 2008.
• Ren Y, Law S, Huang X, Lee PY, Bacher M, Srivastava G and Wong J: Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg 242: 55-63, 2005.
• Kayser K, Nwoye JO, Kosjerina Z, Goldmann T, Vollmer E, Kaltner H, André S and Gabius HJ: Atypical adenomatous hyperplasia of lung: its incidence and analysis of clinical, glycohistochemical and structural features including newly defined growth regulators and vascularization. Lung Cancer 42: 171-182, 2003.
• Wilson JM, Coletta PL, Cuthbert RJ, Scott N, MacLennan K, Hawcroft G, Leng L, Lubetsky JB, Jin KK, Lolis E, Medina F, Brieva JA, Poulsom R, Markham AF, Bucala R and Hull MA: Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 129: 1785-1787, 2005.
• Cuthbert RJ, Wilson JM, Scott N, Coletta PL and Hull MA: Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas. Eur J Cancer 45: 1654-1663, 2009.
• Hyams VJ, Batsakis JG and Michaels L: In: Tumors of the Upper Respiratory Tract and Ear. Atlas of Tumor Pathology. Washington, D.C. Armed Forces Institute of Pathology, pp. 123-6, 1988.
• Wittekind C, Greene FL and Hutter RVP: In: TNM Atlas. 5^th ed. Berlin: UICC Springer, pp. 20-32, 2004.
• Zeng F-Y, Weiser WY, Kratzin H, Stahl B, Karas M and Gabius HJ: The major binding protein of the interferon antagonist sarcolectin in human placenta is a macrophage migration inhibitory factor. Arch Biochem Biophys 303: 74-80, 1993. (Pubitemid 23212661)
• Saussez S, Decaestecker C, Manillon V, Cludts S, Capouillez A, Chevalier D, Vet HK, André S, Toubeau G, Leroy X and Gabius HJ: Galectin-3 upregulation during tumor progression in head and neck cancer. Laryngoscope 118: 1583-1590, 2008.
• Galle N, Pilch BZ and Sidransky D: In: Epithelial Precursor Lesions. World Health Organization Classification of Tumours. Pathololgy and Genetics. Head and Neck Tumours. Lyon-France: IARC Press, pp. 177-9, 2005.
• Saussez S, Decaestecker C, Lorfevre F, Chevalier D, Mortuaire G, Kaltner H, André S, Toubeau G, Gabius HJ and Leroy X: Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and -7 during tumour progression in hypopharyngeal and laryngeal squamous cell carcinomas. Histopathology 52: 483-493, 2008.
• Delorge S, Saussez S, Pelc P, Devroede B, Marchant H, Burchert M, Zeng FY, Danguy A, Salmon I, Gabius HJ, Kiss R and Hassid S: Correlation of galectin-3/galectin-3-binding sites with low differentiation status in head and neck squamous cell carcinomas. Otolaryngol Head Neck Surg 122: 834-841, 2000.
• Choufani G, Ghanooni R, Decaestecker C, Delbrouck K, Simon P, Schüring MP, Zick Y, Hassid S, Gabius HJ and Kiss R: Detection of macrophage migration inhibitory factor (MIF) in human cholesteatomas and functional implications of correlations to recurrence status and to expression of matrix metalloproteinases-3/9, retinoic acid receptor-b, and anti-apoptotic galectin-3. Laryngoscope 111: 1656-1662, 2001.